1 article · following since Nov. 3, 2026 · last update Nov. 3, 2026
In a small phase 1 study published Oct. 30, 2026, in the Journal of the American Academy of Dermatology, low-dose cemiplimab injected into early squamous cell skin cancers left no cancer under the microscope in 58.3% to 66.7% of tumors…